Literature DB >> 35521008

An Exploratory Study of a New Vancomycin Eye Drops Formulation for Extemporaneous Compounding.

Pang Chen1, Zin Mar1, Anthony Giannetti1, Susan Hughes2, Justine Gilbert2, Fang Zhao1.   

Abstract

Purpose: Compounded eye drop solutions of vancomycin hydrochloride have important clinical applications, such as postoperative antimicrobial prophylaxis and bacterial keratitis. There exists a plethora of data to support the use of various liquid vehicles to compound vancomycin hydrochloride eye drops. However, there are a number of limitations for implementation, especially the frequent shortage or discontinuation of the vehicle products. This study was designed to investigate the use of an OTC eye wash product as the evergreen vehicle and to evaluate the physical and chemical stability of the new formulation.
Methods: The Advance Eye Relief® eye wash and vancomycin hydrochloride for injection vials were used to prepare 10 and 50 mg/mL vancomycin eye drop solutions. The solutions were packaged in Steri-Droppers® bottles and stored in a freezer for 14 days followed by 28 days in refrigeration. The 14-day period of freezing was included to allow time for sterility testing. At pre-determined stability time points, samples were taken for visual inspection, pH and osmolality measurement, and analysis by a stability-indicating high performance liquid chromatography (HPLC) method.
Results: Freshly prepared vancomycin eye drops were clear, colorless, and free of particulates. The pH readings were 7.03 and 6.28 for the 10 and 50 mg/mL solutions, respectively. The osmolality of both solutions were within the range of 300-330 mOsmol/kg and considered isotonic. Initial drug concentrations of all samples were confirmed by HPLC to be within 100%-103% of the label claims. Throughout the stability study period, there were no significant changes in the appearance, pH, or osmolality of any samples. The HPLC results also confirmed that the drug concentrations in all stability samples were within 98%-101% of the initial time zero values and no significant degradation product peaks were observed.
Conclusion: A new compounded vancomycin eye drop formulation was developed to mitigate vehicle sourcing issues. This eye drop formulation was easy to prepare, exhibited satisfactory properties for ophthalmic applications, and remained stable chemically and physically when stored for 14 days in freezer followed by 28 days in refrigerator.
© The Author(s) 2020.

Entities:  

Keywords:  antibiotic; compatibility; compounded sterile preparations; ophthalmic; stability

Year:  2020        PMID: 35521008      PMCID: PMC9065524          DOI: 10.1177/0018578720973885

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN: 0018-5787


  12 in total

1.  In vitro stability of fortified ophthalmic antibiotics stored at -20 degrees C for 6 months.

Authors:  Valérie Chédru-Legros; Marguerite Fines-Guyon; Aurélie Chérel; Agathe Perdriel; Françoise Albessard; Danièle Debruyne; Frédéric Mouriaux
Journal:  Cornea       Date:  2010-07       Impact factor: 2.651

Review 2.  Artificial tears potpourri: a literature review.

Authors:  Majid Moshirfar; Kasey Pierson; Kamalani Hanamaikai; Luis Santiago-Caban; Valliammai Muthappan; Samuel F Passi
Journal:  Clin Ophthalmol       Date:  2014-07-31

3.  Stability studies of five anti-infectious eye drops under exhaustive storage conditions.

Authors:  C Curti; E Lamy; N Primas; C Fersing; C Jean; P Bertault-Peres; P Vanelle
Journal:  Pharmazie       Date:  2017-12-01       Impact factor: 1.267

4.  Stability and Sterility of Extemporaneously Prepared Nonpreserved Cefazolin, Ceftazidime, Vancomycin, Amphotericin B, and Methylprednisolone Eye Drops.

Authors:  Nitee Ratprasatporn; Supeecha Wittayalertpanya; Wondee Khemsri; Tanittha Chatsuwan; Yuda Chongpison; Tasanee Chamsai; Mayura Wattanakijkarn; Sunee Chansangpetch
Journal:  Cornea       Date:  2019-08       Impact factor: 2.651

5.  Infectious endophthalmitis in Boston keratoprosthesis: incidence and prevention.

Authors:  Irmgard Behlau; Kathryn V Martin; Jacqueline N Martin; Elena N Naumova; James J Cadorette; J Tammy Sforza; Roberto Pineda; Claes H Dohlman
Journal:  Acta Ophthalmol       Date:  2014-01-25       Impact factor: 3.761

6.  Stability and antibacterial potency of ceftazidime and vancomycin eyedrops reconstituted in BSS against Pseudomonas aeruginosa and Staphylococcus aureus.

Authors:  Vasileios Karampatakis; Theoharis Papanikolaou; Michael Giannousis; Antonis Goulas; Kaliopi Mandraveli; Maria Kilmpasani; Stella Alexiou-Daniel; Vassiliki Mirtsou-Fidani
Journal:  Acta Ophthalmol       Date:  2008-08-12       Impact factor: 3.761

7.  Testing the long term stability of vancomycin ophthalmic solution.

Authors:  Christine McLellan; Van Ngo; Sophia Pasedis; Claes H Dohlman
Journal:  Int J Pharm Compd       Date:  2008 Sep-Oct

8.  Successful prevention of bacterial endophthalmitis in eyes with the Boston keratoprosthesis.

Authors:  Marlene L Durand; Claes H Dohlman
Journal:  Cornea       Date:  2009-09       Impact factor: 2.651

9.  Stability of vancomycin in an extemporaneously compounded ophthalmic solution.

Authors:  L C Fuhrman; R T Stroman
Journal:  Am J Health Syst Pharm       Date:  1998-07-01       Impact factor: 2.637

10.  Application of an experimental design for the optimization and validation of a new HPLC method for the determination of vancomycin in an extemporaneous ophthalmic solution.

Authors:  Montse Enrique; Encarna García-Montoya; Montserrat Miñarro; Anna Orriols; Joseph Ramon Ticó; Joseph Maria Suñé-Negre; Pilar Pérez-Lozano
Journal:  J Chromatogr Sci       Date:  2008-10       Impact factor: 1.618

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.